News
Institute of Cancer Research embraces olaparib recommendation
The Institute of Cancer Research (ICR) has welcomed the ‘life-changing’ decision by the National Institute for Health and Care Excellence (NICE) to recommend AstraZeneca’s olaparib.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The Institute of Cancer Research (ICR) has welcomed the ‘life-changing’ decision by the National Institute for Health and Care Excellence (NICE) to recommend AstraZeneca’s olaparib.